Dyne Therapeutics Posts Wider Loss In Q4
(RTTNews) - Dyne Therapeutics, Inc. (DYN) reported a fourth quarter net loss of $112.0 million, or $0.76 per share compared with a net loss of $89.5 million, or $0.88 per share, a year ago. Research and development expenses were $95.4 million and $81.8 million for the quarters ended December 31, 2025 and 2024, respectively.
Cash, cash equivalents and marketable securities were $1.1 billion as of December 31, 2025. The company continues to expect that its cash, cash equivalents and marketable securities as of December 31, 2025, will be sufficient to fund its operations into the first quarter of 2028.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.